Allergan to Present New Data from its Portfolio of Eye Care Treatments at ARVO

Allergan announced that it will present new data on Vuity(pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) in adults, and Durysta (bimatoprost intracameral implant), a first-of-its-kind biodegradable implant to lower eye pressure for glaucoma patients, at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 1-4 in Denver, Colorado.

"The variety of data we will present will shed light on our continued commitment to innovate in the areas of presbyopia and glaucoma. We are looking forward to unveiling important studies on both Vuity and Durysta to show the advances we are making for those living with these conditions," said Michael R. Robinson, MD, vice president, global therapeutic area head, ophthalmology, AbbVie.   

At the meeting, researchers will present new data on Vuity, a once-daily, prescription eye drop that improves near and intermediate vision without compromising distance vision in patients with age-related blurry near vision. The presentation data will include results from the GEMINI studies on pupil size, depth of focus, and duration of efficacy among other important trial outcomes. 

In addition, attendees will learn of new research findings on Durysta. The presentation will focus on the duration of IOP control following Durysta administration.  

A complete listing of the Allergan ARVO 2022 Annual Meeting abstracts can be viewed at: https://arvo2022.arvo.org/abstracts. 

Details about Allergan's presentations are as follows: